Drugs / MSC-EV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05881668 | Sep 2023 → Sep 2024 | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-EV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05881668 ↗ |
| Known as | mesenchymal stem cells-derived extracellular vesicles | “mesenchymal stem cells-derived extracellular vesicles (MSC-EV) are gradually gaining attention for their enhanced safety” NCT05881668 ↗ |
| Modality | Other / unclassified | “It represents a novel and effective cell-free therapeutic agent as alternative to cell-based therapies for liver diseases” NCT05881668 ↗ |
| Route | Other | “Patients participated in the experimental cohort will be infused with a single dose of 10 E10 MSC-EV particles per 100ml” NCT05881668 ↗ |